![Robert J. Sims](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert J. Sims
Founder at Sims Financial Services LLC
Robert J. Sims active positions
Companies | Position | Start | End |
---|---|---|---|
Sims Financial Services LLC
![]() Sims Financial Services LLC Investment ManagersFinance Sims Financial Services LLC provides investment advice. It offers accumulation, retirement planning, estate planning, risk management and business planning services. The company was founded by Robert J. Sims in 1960 and is headquartered in Wayne, PA. | Founder | 1959-12-31 | - |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Chief Tech/Sci/R&D Officer | - | - |
Founder | - | - |
Career history of Robert J. Sims
Former positions of Robert J. Sims
Companies | Position | Start | End |
---|---|---|---|
CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2017-05-31 | 2019-02-28 |
Training of Robert J. Sims
The University of Texas at Austin | Doctorate Degree |
Statistics
International
United States | 5 |
Operational
Founder | 2 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Sims Financial Services LLC
![]() Sims Financial Services LLC Investment ManagersFinance Sims Financial Services LLC provides investment advice. It offers accumulation, retirement planning, estate planning, risk management and business planning services. The company was founded by Robert J. Sims in 1960 and is headquartered in Wayne, PA. | Finance |
Constellation Pharmaceuticals, Inc.
![]() Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Robert J. Sims
- Experience